三元生物
(301206)
| 流通市值：32.79亿 | | | 总市值：64.14亿 |
| 流通股本：1.03亿 | | | 总股本：2.02亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 191,894,599.16 | 499,500,775.41 | 351,192,635.35 | 235,313,762.07 |
| 营业收入 | 191,894,599.16 | 499,500,775.41 | 351,192,635.35 | 235,313,762.07 |
| 二、营业总成本 | 194,873,387.02 | 550,883,222.33 | 395,084,253.43 | 261,019,478.18 |
| 营业成本 | 175,075,511.64 | 484,265,065.67 | 349,299,318.9 | 235,035,340.17 |
| 税金及附加 | 776,815.2 | 2,688,427.98 | 1,934,795.69 | 1,212,702.36 |
| 销售费用 | 1,233,887.18 | 5,582,615.8 | 3,665,284.79 | 2,444,127.3 |
| 管理费用 | 4,940,584.18 | 15,529,742.01 | 10,916,484.21 | 6,882,274.83 |
| 研发费用 | 15,833,077.03 | 50,661,533.15 | 36,626,985.64 | 21,561,358.95 |
| 财务费用 | -2,986,488.21 | -7,844,162.28 | -7,358,615.8 | -6,116,325.43 |
| 其中:利息收入 | 902,094.27 | 5,354,575.38 | 4,401,728.5 | 3,750,180.62 |
| 加:投资收益 | 27,857,948.97 | 111,749,781.51 | 83,866,978.78 | 56,393,296.16 |
| 资产减值损失(新) | - | -151,109.43 | 4,184,224.37 | 5,164,409.36 |
| 信用减值损失(新) | 15,039.73 | -51,774.38 | -109,277.94 | -46,395.05 |
| 其他收益 | 480,328.97 | 1,214,543.95 | 821,692.01 | 579,858.67 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 25,374,529.81 | 61,378,994.73 | 44,871,999.14 | 36,385,453.03 |
| 加:营业外收入 | 67,716.85 | 333,876.78 | 178,605.82 | 113,959.6 |
| 减:营业外支出 | - | 1,178.55 | 624 | 624 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 25,442,246.66 | 61,711,692.96 | 45,049,980.96 | 36,498,788.63 |
| 减:所得税费用 | 1,194,574.38 | 2,837,243.86 | 3,377,080.39 | 3,181,750.69 |
| 六、净利润 | 24,247,672.28 | 58,874,449.1 | 41,672,900.57 | 33,317,037.94 |
| 持续经营净利润 | 24,247,672.28 | 58,874,449.1 | 41,672,900.57 | 33,317,037.94 |
| 归属于母公司股东的净利润 | 24,247,672.28 | 58,874,449.1 | 41,672,900.57 | 33,317,037.94 |
| (一)基本每股收益 | 0.12 | 0.29 | 0.21 | 0.16 |
| (二)稀释每股收益 | 0.12 | 0.29 | 0.21 | 0.16 |
| 九、综合收益总额 | 24,247,672.28 | 58,874,449.1 | 41,672,900.57 | 33,317,037.94 |
| 归属于母公司股东的综合收益总额 | 24,247,672.28 | 58,874,449.1 | 41,672,900.57 | 33,317,037.94 |
| 公告日期 | 2024-04-23 | 2024-04-23 | 2023-10-27 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |